GH Live signals | Maximize Profits with Getagraph.com

BUY 145 min ago

@ $33.05

Issued: 6 Jun 2023 @ 13:56

Return: -1.15%

Previous signal: Jun 6 - 11:05

Previous signal: Sell

Return: 0.43 %

Live Chart Being Loaded With Signals

Stats
Current Price	$32.67
Today's Volume	1.09M
Average Volume	2.08M
Market Cap	3.83B
EPS	$-7.18
P/E	-4.55
ATR14	$1.470 (4.49%)

Volume Correlation

Long: -0.84 (strong negative)

Short: 0.36 (neutral)

Signal:(55) Neutral

Guardant Health Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Guardant Health Inc Correlation - Currency/Commodity

-0.27
( neutral )

0.36
( neutral )

0.00
( neutral )

-0.60
( weak negative )

0.00
( neutral )

-0.06
( neutral )

Guardant Health Inc Financials

Annual 2022
Revenue: $449.54M
Gross Profit: $293.21M (65.23%)
EPS: $-6.41

Q1 2023
Revenue: $128.71M
Gross Profit: $75.64M (58.77%)
EPS: $-1.300

Q4 2022
Revenue: $126.89M
Gross Profit: $79.77M (62.86%)
EPS: $-1.360

Q3 2022
Revenue: $117.40M
Gross Profit: $76.91M (65.51%)
EPS: $-1.580

Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a strategic collaboration with AnHeart Therapeutics. The company was incorporated in 2011 and is headquartered in Redwood City, California.